Advanced search
Publication Cover
Current Medical Research and Opinion Volume 30, 2014 - Issue 5
Submit an article Journal homepage
888
Views
5
CrossRef citations to date
0
Altmetric
Brief Reports

Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany

R. GökeUniversity of Marburg MarburgGermany
,
J. B. GruenbergerNovartis Pharma AG BaselSwitzerland
,
G. BaderNovartis Pharma AG BaselSwitzerland
&
M. DworakNovartis Pharma GmbH NuernbergGermanyCorrespondence[email protected]
Pages 785-789 | Accepted 10 Dec 2013, Published online: 17 Jan 2014

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Mikkel Z Ankarfeldt, Erpur Adalsteinsson, Rolf HH Groenwold, M Sanni Ali & Olaf H Klungel. (2017) A systematic literature review on the efficacy–effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs. Clinical Epidemiology 9, pages 41-51.
Read now
Thomas Forst & Peter Bramlage. (2014) Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. Expert Opinion on Pharmacotherapy 15:9, pages 1299-1313.
Read now

Articles from other publishers (3)

Artur Mendes Moura, Marília Antunes, Sofia Oliveira Martins & João Filipe Raposo. (2020) A statistical model to identify determinants of glycemic control in patients with type 2 diabetes with different pharmacotherapeutic profiles. PLOS ONE 15:7, pages e0235376.
Crossref
R. Rosales, E. Abou Jaoude, M. Al‐Arouj, A. Fawwad, A. Orabi, P. Shah, S. DiTommaso, J. Vaz & Z. A. Latif. (2015) Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study . Diabetes, Obesity and Metabolism 17:6, pages 603-607.
Crossref
Dominique Simon, Bruno Detournay, Evelyne Eschwege, Stephane Bouée, Jacques Bringer, Claude Attali & Sylvie Dejager. (2014) Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study. Diabetes Therapy 5:1, pages 207-224.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.